Omeros News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.07.17	Biotech Stock Performance Review -- NewLink Genetics, Ocera Therapeutics, Ocular Therapeutix, and Omeros (PR Newswire)
11.07.17	Gainers & Losers Of July 10: KMPH, DOVA, AGLE, LMAT, OCUL... (RTTNews)
29.06.17	Gainers & Losers Of June 28: RARX, ESPR, ASND, FLKS, ALDR... (RTTNews)
15.06.17	Expansion of Global Clinical Trials for Treating an Array of Rare Diseases Boosting Market Growth (PR Newswire)
15.06.17	Expansion of Global Clinical Trials for Treating an Array of Rare Diseases Boosting Market Growth (PR Newswire)
15.06.17	Gainers & Losers Of June 14: OMER, EPZM, ALXN, SBBP, GBT... (RTTNews)
14.06.17	Covered Call reports for Akamai Technologies, Cheesecake Factory, NVIDIA, Omeros and Tesla Motors include trade ideas that offer returns of up to 55% (PR Newswire)
14.06.17	Gainers & Losers Of June 13: ANTH, NK, OMER, GTXI, GNMK... (RTTNews)
13.06.17	Gainers & Losers Of June 12: GTXI, XBIT, NDRM, CHRS, ZYNE... (RTTNews)
18.05.17	Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN... (RTTNews)
11.05.17	FDA Nod For MRK's Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes (RTTNews)
27.04.17	Research Reports Coverage on Biotech Stocks -- Ultragenyx Pharma, Chimerix, Coherus Biosciences, and Omeros (PR Newswire)
17.03.17	Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros (PR Newswire)
02.02.17	Research Reports Coverage on Biotech Stocks -- Anavex Life Sciences, Omeros, Spectrum Pharma, and Lexicon Pharma (PR Newswire)
18.01.17	Quantum Extends Video Surveillance Solutions Portfolio, Grows Partner Ecosystem (PR Newswire)
21.12.16	How These Biotech Stocks are Faring? -- Inovio Pharma, 22nd Century, Omeros, and Cerulean Pharma (PR Newswire)
18.10.16	XENT Breathes Easy, PTCT Suffers Translarna Snub, RTTR To Report Data In Q1 (RTTNews)
09.03.16	ADRO Awaits Data In Q2, All Abuzz At OMER, RDHL Triumphs In H.pylori Study (RTTNews)
04.09.15	AGN Opens Wallet Yet Again, VTL Trims Workforce, First Biosimilar Launched (RTTNews)
19.08.15	Cannabis On A High, PTN Jumps On Sprout News, TNXP At Ease, Watch APHB On Friday (RTTNews)
02.04.15	Omeros Announces U.S. Commercial Launch Of Omidria (RTTNews)
03.06.14	AQXP Goes Sprinting, ARGS On Watch, BIOC Adds New Product, An Insight On RECAP (RTTNews)
02.06.14	FDA Approves Omeros' Omidria For Use In Cataract And ILR Procedures (RTTNews)
03.04.14	FDA Clears Omeros' IND To Evaluate OMS721 In Thrombotic Microangiopathies (RTTNews)
06.03.14	Omeros Phase 2a Trial Of OMS824 Yields More Positive Results (RTTNews)
04.03.14	Omeros Files IND Application With FDA To Initiate Phase 2 For OMS721 (RTTNews)
19.02.14	Omeros Announces Dosing Of First Patient In Second OMS824 Phase 2 Trial (RTTNews)
05.02.14	Omeros: FDA Grants Fast Track Status To OMS824 Huntington's Disease Program (RTTNews)
04.02.14	DXCM Gets FDA Nod, MRK Breathes Easy, Neovasc Takes Heart, VRX Opens Wallet (RTTNews)
03.02.14	Omeros Reports Positive Data After Dosing In Phase 1 Trial With OMS721 (RTTNews)
19.12.13	ALIM, PSDV Rally After Iluvien News, GILD Lays Out Plan, REGN Gets FDA Date (RTTNews)
18.12.13	Omeros' OMS721 Gets Orphan Drug Status From FDA - Quick Facts (RTTNews)
20.11.13	Omeros: FDA Accepts Brand Name Omidria For OMS302 - Quick Facts (RTTNews)
07.11.13	Omeros Announces Positive Data In Phase 1 Trial With OMS721 (RTTNews)
05.11.13	Omeros Reports Positive Data Using OMS721 In MASP-2 Program (RTTNews)
21.10.13	Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros (PR Newswire)
17.10.13	Omeros Corporation Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement (PR Newswire)
17.10.13	Omeros Reports Addl Positive Data For DrugCandidate To Treat Cognitive Disorders (RTTNews)
17.10.13	Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders (PR Newswire)
15.10.13	Upcoming Financial Results Schedules, Clinical Studies and Trials, and New Appointments - Research Report on BioMarin, Alnylam, Aegerion, Omeros, and Tesaro (PR Newswire)
15.10.13	Omeros: FDA Agrees With OMS302 Pediatric Study Plan - Quick Facts (RTTNews)
15.10.13	FDA Agrees with Omeros' Pediatric Study Plan for OMS302 (PR Newswire)
09.10.13	Beating The Street (RTTNews)
09.10.13	Critical Alerts For General Motors, ExOne, Manitowoc, Varian Medical, and Omeros Released By InvestorsObserver (PR Newswire)
08.10.13	Omeros Hires Michael K. Inouye to Lead Commercial Operations (PR Newswire)
07.10.13	Changes in Senior Management, Grants of Orphan Drug Designations, and Updates on Pipeline Development and NDA - Research Report on Vivus, Omeros, Delcath Systems, Achillion, and Zogenix (PR Newswire)
04.10.13	AMRN Faces FDA Panel On Oct.16, Isis Pockets $2Mln, NEOG Effects Stock Split (RTTNews)
03.10.13	Omeros Announces Settlement With Its Insurer - Quick Facts (RTTNews)
02.10.13	US & European Regulators Accept For Review Omeros'OMS302 Marketing Applications (RTTNews)
02.10.13	US and European Regulators Accept for Review OMS302 Marketing Applications (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Omeros Corp

Aktien Top/Flop

Meistgelesene Nachrichten